Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06714591 · ClinicalTrials.gov registry record · Phase 1
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
A Phase 1 study of Relapsed/Refractory Acute Myeloid Leukemia, sponsored by SystImmune.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 14
- Study locations
NCT06714591 is a Phase 1 study of Relapsed/Refractory Acute Myeloid Leukemia that is actively recruiting participants, run by SystImmune. The registered enrollment target is 120 participants. The trial reports 14 study locations across 10 states.
The verdict
NCT06714591, a Phase 1 study of Relapsed/Refractory Acute Myeloid Leukemia, is actively recruiting participants, sponsored by SystImmune.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 14
- Study locations
Study Summary
The objective of this study to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia.
Conditions Studied
Interventions
- DRUG BL-M11D1
Study Locations (14)
California
- City of Hope - Duarte
- UCLA Ronald Reagan Medical Center - Los Angeles
Ohio
- Oncology Hematology Care Clinical Trials, LLC - Cincinnati
- The Ohio State University Comprehensive Cancer Center - Columbus
Texas
- MD Anderson Cancer Center - Houston
- Texas Oncology, P.A. - San Antonio
Virginia
- Virginia Cancer Specialists - Fairfax
- Oncology & Hematology Associates of Southwest Virginia, Inc. - Roanoke
Connecticut
- Yale Cancer Center, Smilow Cancer Hospital at Yale New Haven - New Haven
Florida
- Moffitt Cancer Center - Tampa
Michigan
- START Midwest/The Cancer and Hematology Center - Grand Rapids
Oregon
- WVCI Oncology Associates of Oregon - Eugene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-12-19 |
| Est. Completion | 2027-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06714591
The ClinicalTrials.gov registry entry for NCT06714591 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SystImmune, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed/Refractory Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which BL-M11D1 is the first listed.
NCT06714591 reports 14 study locations spanning 10 distinct geographic areas - top geographies include California, Ohio, Texas.
Frequently Asked Questions
What is clinical trial NCT06714591 about?
NCT06714591 is a clinical study titled "Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1". The objective of this study to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia.
What is the current status of trial NCT06714591?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2024-12-19. Estimated completion is 2027-03-30.
What conditions does trial NCT06714591 study?
This clinical trial studies the following conditions: Relapsed/Refractory Acute Myeloid Leukemia.
What interventions are being tested in trial NCT06714591?
The interventions under investigation include: BL-M11D1 (DRUG).
Who is sponsoring clinical trial NCT06714591?
This trial is sponsored by SystImmune, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06714591 being conducted?
This trial has 14 study locations across California, Connecticut, Florida, Michigan, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed/Refractory Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.